Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neuromyelitis Optica 1Myasthenia Gravis 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

fludarabine phosphate 11Cyclophosphamide 11Whole-Body Irradiation 8Mycophenolic Acid 8Busulfan 7fludarabine 6Tacrolimus 6Peripheral Blood Stem Cell Transplantation 6Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3thymoglobulin 3apixaban 3Methotrexate 3Cyclosporine 3Antilymphocyte Serum 3decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ravulizumab × Classical hematology × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔